Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pharmasset, Inc.
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
Coloplast expects Kerecis' rapid growth to justify the high price of the acquisition. The Icelandic company's skin-substitute products are made from minimally processed cod skins.
The sizzling race for China’s first approved KRAS inhibitor has seen Amgen/BeiGene’s Lumakras drop out and Mirati/Zai Lab’s Krazati lag in a confirmatory Phase III trial, while domestic fast-followers are in the meantime eyeing their first approval filings by the end of this year.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.